

MINISTRY OF PUBLIC HEALTH OF UKRAINE
NATIONAL UNIVERSITY OF PHARMACY

**TOPICAL ISSUES
OF NEW DRUGS DEVELOPMENT**

Vol. 2

April 20, 2017

Kharkiv

Kharkiv

NUPh

2017

13. MODERN PHARMACOTHERAPY	149
Aravina V. V.; Sc. s.: Kireev I. V.	150
Bunyatyan N. D., Oborotova N. A., Nikolaeva L. L.	151
Butenko O. F.; Sc. s.: Ryabova O. O.	152
Dercach A. O.; Sc. s.: Tryshchuk N. M.	153
Gubenko E. S.; Sc. s.: Kashuta V. E.	154
Kovalenko I. S., Semchenko A. S.; Sc. s.: Zhabotynska N. V.	155
Krivykh M. A., Kornilova O. G., Bunyatyan N. D., Mosyagin V. D., Bondarev V. P., Olefir J. V.	156
Lavrova A. D.; Sc. s.: Ryabova O. O.	157
Lukianchuk J. O.; Sc. s.: Drogovoz S. M.	158
Lytvynenko Y. Y.; Sc. s.: Kashuta V. E.	159
Mirenkova P. V.; Sc. s.: Savokhina M. V.	160
Morgunov A. V.; Sc. s.: Tryshchuk N. M.	161
Prystenska A. V.; Sc. s.: Ryabova O. O.	162
Putnenko N. A.; Sc. s.: Zhabotynska N. V.	163
Rakeev P.; Sc. s.: Drogovoz S. M.	164
Tolmacheva K. S.; Sc. s.: Kireev I. V.	165
Vodolazskaya Y. A.; Sc. s.: Tryshchuk N. M.	166
Żmudzka E., Lustyk K., Jakubczyk M., Jaśkowska J., Kołaczkowski M.; Sc. s.: Sapa J., Pytka K.	167
	168
14. PHARMACOECONOMIC STUDIES OF DRUGS	170
Ashfennar Sarah; Sc. s.: Gerasymova O. A.	171
Berdnik O.G.; Sc. s.: Tsubanova N. A.	172
Gorbachenko C.; Sc. s.: Matyashova N.A.	173
Jaloliddinova M. Sh, Zufarova Z. Kh.; Sc. s.: Yunusova Kh. M.	174
Lotfi El Mehdi; Sc. s.: Tkachova O. V., Sakharova T. S.	176
Podgainaya V. L.; Sc. s.: Bezditko N. V.	177
Sharifov Ch. Sh.; Sc. s.: Zaychenko G. V., Mishchenko O. Ya., Khalieieva O. L.	178
Voznyak I. V., Bondarenko O. I.; Sc. s.: Mishchenko O. Ya., Ostashko V. F.	179
15. MANAGEMENT AND MARKETING IN PHARMACY	180
Al Batat Alaa Kadhim Ali; Sc. s.: Sofronova I. V.	181
Aliyeva L. S., Kobets M. N., Kobets Yu. N.	182
Al-Obaidi Mustafa Sameer Abdolwahhab; Sc. s.: Sofronova I. V.	183
Mala Zh. V.; Sc. s.: Posylkina O. V.	184
Postoy V. V.; Sc. s.: Vyshnevskaya L. I.	185
Pyrylyk D. O.; Sc. s.: Bondarieva I. V.	186
Rouached R.; Sc. s.: Zhadko S. V.	187

THE RATIONALITY OF THE DRUGS PRESCRIPTIONS FOR PATIENTS WITH CORONARY HEART DISEASE IN MEDICAL INSTITUTIONS OF UKRAINE

Voznyak I. V., Bondarenko O. I.

Scientific supervisors: prof. Mishchenko O. Ya., assist. prof. Ostashko V. F.

National University of Pharmacy, Kharkiv, Ukraine

clinpharmacol_ipksph@nuph.edu.ua

Introduction. Coronary heart disease is the leading cause of death in the world and in Ukraine. The results of clinical and economic analysis of efficacy and safety of therapy enhances its rationality.

Aim. Assessment of the rationality of pharmacotherapy of patients with coronary heart disease according to the results of VEN-analysis.

Materials and methods. The formal VEN-analysis was used in accordance with the state normative documents: Unified clinical protocol of primary, secondary (specialized) and tertiary (highly specialized) medical care "Stable coronary heart disease" (2016) and the State Formulary of drugs in Ukraine (2015). VEN-analysis assumes the distribution of drugs in terms of their importance in two categories: "V" – vital and "N" (non-essential). In the presence of an international non-proprietary name in the specified normative documents, which were developed taking into account the modern requirements of evidence-based medicine, these drugs were classified as "V".

Results and discussion. A retrospective analysis of prescribing lists of 100 patients from the average statistical treatment and prophylactic institution of Ukraine was carried out. "Coronary heart disease" was the main diagnosis in all patients. The patients had polymorbidity of the pathology, which caused polypragmasia. The main directions of pharmacotherapy of coronary heart disease were: anti-ischemic, antiplatelet and lipid-lowering, which correspond to normative documents. The number of prescriptions per patient – 11.1. A formal VEN-analysis of treatment of patients with coronary heart disease showed that there were 52 (75%) of the 69 international nonproprietary names that were vital (category "V"), non-essential (category "N") were 17 (25%). Group of drugs of the category "N" were: mexidol, meldonium, citicoline, L-lysine escinate, dexketoprofen, piracetam+tiotriazoline, actovegin, corvitin etc.

Conclusions. The results of VEN-analysis show that the main directions of therapy for patients with coronary heart disease corresponded to the requirements of the current clinical protocol and the State Formulary of drugs of Ukraine (2015), in general, but it is possible to improve the rationality of prescriptions by reducing the prescriptions of secondary drugs.